1. Home
  2. OPRX vs KRRO Comparison

OPRX vs KRRO Comparison

Compare OPRX & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OptimizeRx Corporation

OPRX

OptimizeRx Corporation

HOLD

Current Price

$8.74

Market Cap

161.0M

ML Signal

HOLD

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

HOLD

Current Price

$8.90

Market Cap

142.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPRX
KRRO
Founded
2006
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
161.0M
142.0M
IPO Year
2008
2019

Fundamental Metrics

Financial Performance
Metric
OPRX
KRRO
Price
$8.74
$8.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
11
Target Price
$12.60
★ $20.20
AVG Volume (30 Days)
★ 168.6K
162.2K
Earning Date
11-05-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 124.55
N/A
EPS
★ N/A
N/A
Revenue
★ $109,429,000.00
$6,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$10.77
$56.67
P/E Ratio
★ N/A
N/A
Revenue Growth
18.78
★ 181.46
52 Week Low
$4.54
$5.20
52 Week High
$22.25
$46.28

Technical Indicators

Market Signals
Indicator
OPRX
KRRO
Relative Strength Index (RSI) 57.28 34.73
Support Level $6.92 $8.29
Resistance Level $9.13 $14.32
Average True Range (ATR) 0.41 0.75
MACD -0.01 -0.05
Stochastic Oscillator 42.99 9.43

Price Performance

Historical Comparison
OPRX
KRRO

About OPRX OptimizeRx Corporation

OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: